北京先通国际医药科技股份有限公司获证监会备案通知书 拟于香港联合交易所上市

Core Points - The China Securities Regulatory Commission (CSRC) has issued a filing notice confirming the overseas issuance and "full circulation" of shares for Beijing Xiantong International Pharmaceutical Technology Co., Ltd [1] - The company plans to issue no more than 9.26 million overseas listed ordinary shares and list them on the Hong Kong Stock Exchange [1] - A total of 95 shareholders will convert a combined 34.466 million shares of unlisted domestic shares into overseas listed shares [1][2] Summary by Sections - Company's Actions - The company is set to issue up to 9.26 million shares for overseas listing [1] - 95 shareholders will convert 34.466 million unlisted domestic shares into overseas shares [1][2] - Regulatory Requirements - The CSRC requires the company to report any significant events from the date of the notice until the completion of the overseas issuance [1] - The company must report the issuance status within 15 working days after the completion of the overseas listing [1] - If the overseas issuance and share conversion are not completed within 12 months, the company must update the filing materials [1] - Shareholder Participation - The largest conversion comes from Xu Xinsheng with 3.343 million shares, followed by Jiangsu Diquan Chengda Equity Investment Center and Jinshi Manufacturing Transformation Upgrade New Materials Fund with 2.959 million and 2.276 million shares respectively [2]